Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.

CONTEXT

Sildenafil increases insulin sensitivity in mice. In humans, phosphodiesterase 5 inhibition improves disposition index, but the mechanism of this effect has not been elucidated and may depend on duration. In addition, increasing cyclic GMP without increasing nitric oxide could have beneficial effects on fibrinolytic balance.

OBJECTIVE

The objective was to test the hypothesis that chronic phosphodiesterase 5 inhibition with sildenafil improves insulin sensitivity and secretion without diminishing fibrinolytic function.

DESIGN

This was a randomized, double-blind, placebo-controlled study.

SETTING

This trial was conducted at Vanderbilt Clinical Research Center.

PARTICIPANTS

Participants included overweight individuals with prediabetes.

INTERVENTIONS

Subjects were randomized to treatment with sildenafil 25 mg three times a day or matching placebo for 3 months. Subjects underwent a hyperglycemic clamp prior to and at the end of treatment.

MAIN OUTCOME MEASURES

The primary outcomes of the study were insulin sensitivity and glucose-stimulated insulin secretion.

RESULT

Twenty-one subjects completed each treatment arm. After 3 months, the insulin sensitivity index was significantly greater in the sildenafil group compared to the placebo group by 1.84 mg/kg/min per μU/mL100 (95% confidence interval, 0.01 to 3.67 mg/kg/min per μU/mL100; P = .049), after adjusting for baseline insulin sensitivity index and body mass index. In contrast, there was no effect of 3-month treatment with sildenafil on acute- or late-phase glucose-stimulated insulin secretion (P > .30). Sildenafil decreased plasminogen activator inhibitor-1 (P = .01), without altering tissue-plasminogen activator. In contrast to placebo, sildenafil also decreased the urine albumin-to-creatinine ratio from 12.67 ± 14.67 to 6.84 ± 4.86 μg/mg Cr. This effect persisted 3 months after sildenafil discontinuation.

CONCLUSIONS

Three-month phosphodiesterase 5 inhibition enhances insulin sensitivity and improves markers of endothelial function.